See more : Rousselet Centrifugation S.A. (MLROU.PA) Income Statement Analysis – Financial Results
Complete financial analysis of HUTCHMED (China) Limited (0013.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HUTCHMED (China) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Daidong Electronics Co. Ltd. (008110.KS) Income Statement Analysis – Financial Results
- Khang Dien House Trading and Investment Joint Stock Company (KDH.VN) Income Statement Analysis – Financial Results
- CTOS Digital Bhd (5301.KL) Income Statement Analysis – Financial Results
- Tbi Motion Technology Co., Ltd. (4540.TW) Income Statement Analysis – Financial Results
- Horizon Acquisition Corporation II (HZON-UN) Income Statement Analysis – Financial Results
HUTCHMED (China) Limited (0013.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hutch-med.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 838.00M | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M | 241.20M | 216.08M | 178.20M | 91.81M | 45.97M | 195.39M | 166.92M | 134.51M | 111.00M | 86.97M | 65.11M | 50.43M | 37.86M |
| Cost of Revenue | 384.45M | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M | 175.82M | 156.33M | 110.78M | 72.05M | 22.21M | 99.40M | 74.16M | 54.64M | 44.59M | 36.13M | 27.66M | 21.32M | 14.62M |
| Gross Profit | 453.55M | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M | 65.38M | 59.75M | 67.43M | 19.76M | 23.76M | 95.99M | 92.77M | 79.87M | 66.41M | 50.84M | 37.45M | 29.11M | 23.24M |
| Gross Profit Ratio | 54.12% | 27.04% | 27.49% | 17.31% | 21.84% | 32.77% | 27.11% | 27.65% | 37.84% | 21.53% | 51.69% | 49.13% | 55.57% | 59.38% | 59.83% | 58.46% | 57.52% | 57.72% | 61.40% |
| Research & Development | 302.00M | 267.59M | 207.45M | 111.23M | 91.94M | 78.82M | 50.68M | 66.87M | 47.37M | 33.47M | 23.44M | 5.89M | 7.29M | 6.41M | 3.86M | 8.81M | 5.64M | 2.77M | 2.05M |
| General & Administrative | 79.78M | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M | 23.96M | 21.58M | 19.62M | 22.57M | 21.30M | 35.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 53.39M | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M | 19.32M | 18.00M | 10.21M | 4.11M | 3.45M | 62.68M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| SG&A | 133.18M | 136.11M | 127.13M | 61.35M | 52.93M | 48.65M | 43.28M | 39.58M | 29.83M | 26.68M | 24.75M | 98.41M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| Other Expenses | -303.05M | 119.31M | 91.64M | 63.54M | 44.88M | -781.00K | 116.00K | 609.00K | 184.00K | 261.00K | 65.00K | -1.01M | 23.39M | -225.46K | -282.96K | -1.22M | -937.60K | -557.58K | -175.47K |
| Operating Expenses | 453.55M | 523.00M | 426.21M | 236.13M | 189.76M | 161.01M | 118.80M | 106.59M | 77.20M | 26.87M | 23.14M | 95.36M | 87.18M | 82.46M | 71.51M | 64.98M | 47.36M | 34.50M | 29.16M |
| Cost & Expenses | 819.62M | 834.10M | 684.45M | 424.64M | 349.91M | 304.95M | 294.62M | 262.92M | 187.97M | 98.92M | 45.35M | 194.76M | 161.34M | 137.10M | 116.10M | 101.11M | 75.01M | 55.82M | 43.77M |
| Interest Income | 36.15M | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M | 1.22M | 502.00K | 451.00K | 559.00K | 451.00K | 578.00K | 133.65K | 225.46K | 282.96K | 1.22M | 937.60K | 559.54K | 175.47K |
| Interest Expense | 759.00K | 652.00K | 592.00K | 787.00K | 1.03M | 1.01M | 1.46M | 1.63M | 1.40M | 1.05M | 1.01M | 737.00K | 561.03K | 402.38K | 399.37K | 527.87K | 299.15K | 388.73K | 495.45K |
| Depreciation & Amortization | 8.21M | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M | 2.58M | 2.34M | 2.02M | 1.27M | 963.00K | 4.05M | 4.56M | 4.58M | 4.57M | 4.65M | 3.80M | 2.87M | 2.32M |
| EBITDA | 67.27M | -401.11M | -329.27M | -182.89M | -135.13M | -82.06M | -49.50M | -43.38M | -7.12M | -17.01M | 12.05M | 14.07M | 11.32M | 2.37M | -46.89K | -9.58M | -5.92M | -2.51M | -3.42M |
| EBITDA Ratio | 8.03% | -94.07% | -92.46% | -80.22% | -65.95% | -38.32% | -20.52% | -20.08% | -4.00% | -6.36% | 3.44% | -3.48% | 6.11% | 2.01% | 0.13% | -10.88% | -8.61% | -4.83% | -9.51% |
| Operating Income | 18.38M | -409.77M | -336.46M | -188.95M | -145.02M | -92.64M | -53.42M | -46.70M | -9.77M | 8.10M | 11.56M | 12.11M | 5.39M | -2.21M | -4.61M | -14.23M | -9.72M | -5.38M | -5.73M |
| Operating Income Ratio | 2.19% | -96.10% | -94.48% | -82.88% | -70.78% | -43.27% | -22.15% | -21.61% | -5.48% | 8.82% | 25.14% | 6.20% | 3.23% | -1.64% | -4.16% | -16.36% | -14.93% | -10.67% | -15.13% |
| Total Other Income/Expenses | 87.23M | -2.73M | 173.19M | 85.98M | 45.98M | 25.32M | -119.00K | -659.00K | -769.00K | 13.48M | -1.49M | 29.31M | -561.00K | -402.38K | -399.37K | -527.87K | -299.15K | -386.77K | -502.33K |
| Income Before Tax | 105.60M | -410.42M | -215.74M | -189.73M | -141.11M | -86.66M | -53.54M | -47.36M | -10.54M | 6.58M | 10.07M | 10.90M | 4.83M | -2.61M | -5.01M | -14.76M | -10.02M | -5.77M | -6.23M |
| Income Before Tax Ratio | 12.60% | -96.25% | -60.58% | -83.23% | -68.87% | -40.47% | -22.20% | -21.92% | -5.91% | 7.17% | 21.91% | 5.58% | 2.89% | -1.94% | -4.52% | -16.97% | -15.39% | -11.44% | -16.46% |
| Income Tax Expense | 4.51M | -283.00K | 11.92M | 4.83M | 3.27M | 3.96M | 3.08M | 4.33M | 1.61M | 1.34M | 1.05M | 4.16M | 3.14M | 2.58M | 2.07M | 1.50M | 837.21K | 1.96K | 141.06K |
| Net Income | 100.78M | -410.14M | -227.66M | -194.56M | -144.38M | -74.81M | -26.74M | 11.70M | 7.99M | 5.37M | 5.92M | 3.64M | 710.22K | -6.86M | -8.75M | -17.76M | -17.19M | -9.61M | -6.78M |
| Net Income Ratio | 12.03% | -96.18% | -63.93% | -85.34% | -70.47% | -34.94% | -11.08% | 5.41% | 4.49% | 5.85% | 12.87% | 1.86% | 0.43% | -5.10% | -7.88% | -20.41% | -26.40% | -19.05% | -17.90% |
| EPS | 0.12 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.02 | -0.06 | 0.01 | 0.01 | 0.01 | 0.00 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | 0.12 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.02 | -0.06 | 0.01 | 0.01 | 0.01 | 0.00 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 849.66M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 597.15M | 546.59M | 525.63M | 520.51M | 519.19M | 517.43M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
| Weighted Avg Shares Out (Dil) | 869.20M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 599.71M | 546.59M | 528.94M | 528.78M | 526.50M | 526.54M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
Source: https://incomestatements.info
Category: Stock Reports